Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed with Clade 1 Influenza A(H5N1) Vaccine

Journal of Infectious Diseases

Volumn 212, Issue 4, 2015, Pages 525-530

  Winokur, Patricia L ^a   Patel, Shital M ^b,c   Brady, Rebecca ^d   Chen, Wilbur H ^e   El Kamary, Samer S ^e   Edwards, Kathryn ^g   Creech, C Buddy ^g   Frey, Sharon ^h   Keitel, Wendy A ^c   Belshe, Robert ^h   Walter, Emmanuel ⁱ   Bellamy, Abbie ^f   Hill, Heather ^f  

^a UNIVERSITY OF IOWA   (United States)

^b Department of Medicine ^*  (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e University of Maryland School of Medicine Center for Vaccine Development   (United States)

^f EMMES CORPORATION   (United States)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^h SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

H5N1; influenza; prime boost; vaccine

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADULT; ANTIBODY TITER; ANTIGENICITY; ARTICLE; CLADISTICS; CONTROLLED STUDY; CROSS REACTION; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA A (H5N1); LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VACCINATION; AGED; BLOOD; CLASSIFICATION; CLINICAL TRIAL; DOSE RESPONSE; GENETICS; IMMUNIZATION; IMMUNOLOGY; INFLUENZA A VIRUS (H5N1); INFLUENZA, HUMAN; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SERODIAGNOSIS; VIROLOGY; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, VIRAL; CROSS REACTIONS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84939620851     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv087     Document Type: Article

References (15)

1. WHO/OIE/FAO H5N1Working Group. Continued evolution of highly pathogenic avian influenza A (H5N1): updated nomenclature. Influenza Other Respi Viruses 2012; 6:1-5.
2. Baz M, Luke CJ, Cheng X, Jin H, Subbarao K. H5N1 vaccines in humans. Virus Res 2013; 178:78-98.
3. Stephenson I, Bugarini R, Nicholson KG, et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005; 191:1210-5.
4. Zangwill KM, Treanor JJ, Campbell JD, Noah DL, Ryea J. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis 2008; 197:580-3.
5. Goji NA, Nolan C, Hill H, et al. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis 2008; 198:635-41.
6. Noah DL, Hill H, Hines D, White EL, Wolff MC. Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure. Clin Vaccine Immunol 2009; 16:558-66.
7. Arinaminpathy N, Ratmann O, Koelle K, et al. Impact of cross-protective vaccines on epidemiological and evolutionary dynamics of influenza. Proc Natl Acad Sci USA 2012; 109:3173-7.
8. Germann TC, Kadau K, Longini IM Jr, Macken CA. Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci USA 2006; 103:5935-40.
9. Galli G, Hancock K, Hoschler K, et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci USA 2009; 106:7962-7.
10. Schwarz TF, Horacek T, Knuf M, et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009; 27:6284-90.
11. Belshe RB, Frey SE, Graham I, et al. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. J Infect Dis 2011; 203:666-73.
12. Nolan T, Richmond PC, Formica NT, et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 2008; 26:6383-91.
13. Ohmit SE, Petrie JG, Malosh RE, et al. Influenza vaccine effectiveness in the community and the household. Clin Infect Dis 2013; 56:1363-9.
14. Smith DJ, Forrest S, Ackley DH, Perelson AS. Variable efficacy of repeated annual influenza vaccination. Proc Natl Acad SciUSA 1999; 96:14001-6.
15. Li GM, Chiu C, Wrammert J, et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci USA 2012; 109:9047-52.